Peptide receptor radionuclide therapy (PRRT) for GEP-NETs
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs
复制标题
DOI：
10.1016/j.bpg.2013.01.004
复制
发表时间：
2012-12-01
影响因子：
3.2
通讯作者：
Kwekkeboom, Dik J.
中科院分区：
文献类型：
--
作者：
Bergsma, Hendrik;van Vliet, Esther I.;Kwekkeboom, Dik J.
放射性标记生长抑素类似物的肽受体放射性核素治疗（PRRT）在治疗不可手术或转移的胃肠胰腺神经内分泌肿瘤（GEP-NET）患者中发挥着越来越重要的作用。Y-90-DOTATOC和Lu-177-DOTATATE是PRRT中最常用的放射性肽，肿瘤缓解率相当（约15-35%）。这种疗法的副作用很少而且轻微。然而，氨基酸应用于肾脏保护，特别是在Y-90-DOTATOC输注期间。改善PRRT的选择可能包括放射性标记的生长抑素类似物的组合和使用放射增敏药物与PRRT相结合。PRRT的其他治疗应用可能包括动脉内给药，新辅助治疗和额外的PRRT周期，在疾病进展的患者中，谁已经从初始治疗中受益，考虑到轻微的副作用，PRRT很可能成为一线治疗转移或不能手术的GEP-NETs患者，如果更广泛地使用PRRT可以实现。(C)2013爱思唯尔有限公司保留所有权利。
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). Y-90-DOTATOC and Lu-177-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response rates (about 15-35%). The side effects of this therapy are few and mild. However, amino acids should be used for kidney protection, especially during infusion of Y-90-DOTATOC. Options to improve PRRT may include combinations of radioactive labelled somatostatin analogues and the use of radio-sensitising drugs combined with PRRT. Other therapeutic applications of PRRT may include intra-arterial administration, neoadjuvant treatment and additional PRRT cycles in patients with progressive disease, who have benefited from initial therapy.Considering the mild side-effects, PRRT may well become the first-line therapy in patients with metastasised or inoperable GEP-NETs if more widespread use of PRRT can be accomplished. (C) 2013 Elsevier Ltd. All rights reserved.